Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune checkpoint inhibitor combinations—current and emerging strategies
Robert J. Walsh, Raghav Sundar, Joline S.J. Lim
British Journal of Cancer (2023) Vol. 128, Iss. 8, pp. 1415-1417
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 52
Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
Norah A. Alturki
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4301-4301
Open Access | Times Cited: 50
Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade
Young‐Jin Choi, Su Hyun Seok, Hong Yeol Yoon, et al.
Advanced Drug Delivery Reviews (2024) Vol. 209, pp. 115306-115306
Open Access | Times Cited: 19
CD73/adenosine dynamics in treatment-induced pneumonitis: balancing efficacy with risks of adverse events in combined radio-immunotherapies
Lena Gockeln, Florian Wirsdörfer, Verena Jendrossek
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access | Times Cited: 1
Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies
D.Y. Luo, Jing Zhou, Shuiliang Ruan, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Seyed Hossein Kiaie, Hossein Salehi‐Shadkami, Mohammad‐Javad Sanaei, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 35
Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors
Anna Pawłowska, Anna K. Rekowska, Weronika Kuryło, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10859-10859
Open Access | Times Cited: 24
Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy
Suling Xu, Qing-Qing Wang, Wenxue Ma
Cytokine & Growth Factor Reviews (2024) Vol. 76, pp. 12-21
Closed Access | Times Cited: 12
Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment
Racheli Birnboim-Perach, Itai Benhar
International Journal of Biological Sciences (2024) Vol. 20, Iss. 10, pp. 3911-3922
Open Access | Times Cited: 10
PARP Inhibitors in Breast Cancer: a Short Communication
Gordon R. Daly, Maen Monketh Alrawashdeh, Jason McGrath, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 2, pp. 103-113
Open Access | Times Cited: 8
Nuclear PD-L1 triggers tumour-associated inflammation upon DNA damage
Naoe Taira Nihira, Wenwen Wu, M Hosoi, et al.
EMBO Reports (2025)
Open Access | Times Cited: 1
The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition
Jeroen van Dorp, Michiel S. van der Heijden
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Engineering nanoparticles for cancer immunotherapy: Current achievements, key considerations and future perspectives
Muhammad Umar Farooq, Charles H. Lawrie, Nan‐Nan Deng
Chemical Engineering Journal (2024) Vol. 486, pp. 150356-150356
Closed Access | Times Cited: 7
Persistent T cell unresponsiveness associated with chronic visceral leishmaniasis in HIV-coinfected patients
Nicky de Vrij, Julia Pollmann, Antônio Mauro Rezende, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 5
Human NK cells and cancer
Claudia Cantoni, Michela Falco, Massimo Vitale, et al.
OncoImmunology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Nanotechnology Applications in Breast Cancer Immunotherapy
Ruijie Wang, Pramod Kumar, Moataz Reda, et al.
Small (2023)
Closed Access | Times Cited: 13
Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer
Markéta Skaličková, Katerina Hadrava Vanova, Ondřej Uher, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Toxicity Associated with Pembrolizumab Monotherapy in Patients with Gastrointestinal Cancers: A Systematic Review of Clinical Trials
Nikolas Naleid, Amit Mahipal, Sakti Chakrabarti
Biomedicines (2025) Vol. 13, Iss. 1, pp. 229-229
Open Access
Dendritic Cell-Based Glioblastoma Vaccines: Advances and Challenges
Zuowen Zhang, Mingchang Li, Jie Huang
IntechOpen eBooks (2025)
Closed Access
Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8+T cell activity and Fcγ receptor-mediated modulation of the tumor microenvironment
Wonjun Son, Yangsoon Lee, Yelim Park, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e010728-e010728
Open Access
Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial
Yuan Gao, Ann‐Lii Cheng, Lee X. Li, et al.
International Journal of Cancer (2025)
Open Access
Autophagy in tumor immune escape and immunotherapy
Huan Wang, Peng Sun, Xijing Yuan, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Single-nucleus RNA sequencing reveals heterogenous microenvironments and specific drug response between cervical squamous cell carcinoma and adenocarcinoma
Shitong Lin, Yuanhui Sun, Canhui Cao, et al.
EBioMedicine (2023) Vol. 97, pp. 104846-104846
Open Access | Times Cited: 11
Inconsistency in steroid use as antiemetics in clinical trial protocols involving immune checkpoint inhibitors combined with chemotherapy
Soh Mee Park, Yu Jung Kim, Ju‐Yeun Lee
Cancer Medicine (2024) Vol. 13, Iss. 7
Open Access | Times Cited: 2
d-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunity
Wenjing Dong, Mingen Lin, Ruonan Zhang, et al.
Cancer Letters (2024) Vol. 591, pp. 216883-216883
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top